Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-anti-CD66 plus melphalan versus melphalan alone before autologous stem cell transplantation for multiple myeloma
ISRCTN11933044Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- May 2007
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
01
Overview
Phase 2, open-label trial of 90Y-besilesomab, melphalan and indium-111-labelled anti-CD66 monoclonal antibody in multiple myeloma (MM) (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Complete remission rate and remission status. Started May 2007; status: completed.
02
Drugs
90Y-besilesomabmelphalanindium-111-labelled anti-CD66 monoclonal antibody
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN11933044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11933044.